Sensei Biotherapeutics Faces Nasdaq Delisting Warning
Ticker: SNSE · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Jul 12, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00, $5,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, stock-price
Related Tickers: SNSE
TL;DR
Nasdaq says Sensei Bio's stock price is too low, giving them until Jan 2025 to fix it or get booted.
AI Summary
Sensei Biotherapeutics, Inc. announced on July 10, 2024, that it received a notification from the Nasdaq Stock Market indicating a failure to meet the minimum bid price requirement for continued listing. The company has 180 calendar days, until January 6, 2025, to regain compliance.
Why It Matters
This notification signals potential financial distress and could impact the company's ability to raise capital and its stock's liquidity.
Risk Assessment
Risk Level: high — Failure to meet continued listing requirements on a major exchange like Nasdaq significantly increases the risk of delisting, which can severely impact stock value and liquidity.
Key Numbers
- 180 — calendar days (Timeframe to regain compliance)
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange issuing delisting notification
- July 10, 2024 (date) — Date of notification
- January 6, 2025 (date) — Deadline for compliance
FAQ
What specific continued listing rule did Sensei Biotherapeutics fail to meet?
The filing indicates a failure to meet the minimum bid price requirement for continued listing on the Nasdaq Stock Market.
When did Sensei Biotherapeutics receive the notification from Nasdaq?
The company received the notification on July 10, 2024.
What is the deadline for Sensei Biotherapeutics to regain compliance with Nasdaq's listing rules?
The company has until January 6, 2025, to regain compliance.
What is the primary consequence of failing to regain compliance?
The primary consequence is the potential delisting of the company's securities from the Nasdaq Stock Market.
What is Sensei Biotherapeutics' principal executive office address?
The principal executive offices are located at 1405 Research Blvd, Suite 125, Rockville, MD 20850.
Filing Stats: 855 words · 3 min read · ~3 pages · Grade level 13.8 · Accepted 2024-07-12 16:31:03
Key Financial Figures
- $1.00 — he Company's common stock was less than $1.00 per share for the previous 30 consecuti
- $5,000 — to submit a Transfer Application and a $5,000 application fee. In addition, the Compa
Filing Documents
- d853366d8k.htm (8-K) — 28KB
- 0001193125-24-178607.txt ( ) — 186KB
- snse-20240710.xsd (EX-101.SCH) — 4KB
- snse-20240710_def.xml (EX-101.DEF) — 14KB
- snse-20240710_lab.xml (EX-101.LAB) — 23KB
- snse-20240710_pre.xml (EX-101.PRE) — 15KB
- d853366d8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: July 12, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3